{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:56:48Z","timestamp":1775102208666,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.gastrohep.2024.502276","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T17:57:54Z","timestamp":1729274274000},"page":"502276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tenofovir alafenamide versus entecavir in treating patients with chronic hepatitis B: A meta-analysis"],"prefix":"10.1016","volume":"48","author":[{"given":"Jian-Xing","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2024.502276_bib0200","first-page":"1","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B","volume":"36","year":"2023","journal-title":"Infect Dis Info"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0205","unstructured":"World Health Organization. Hepatitis B. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"10.1016\/j.gastrohep.2024.502276_bib0210","first-page":"153","article-title":"Multiple diagnostic indicators in the development of chronic hepatitis B liver cirrhosis, and liver cancer","volume":"29","author":"Yang","year":"2023","journal-title":"Altern Ther Health Med"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0215","first-page":"2","article-title":"Risk of HCC in individuals of sub-Saharan ethnicity or descent with chronic hepatitis B in Europe","volume":"21","author":"Ray","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0220","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.3346\/jkms.2024.39.e59","article-title":"Is the prevalence of chronic hepatitis B really increasing in Korea?","volume":"39","author":"Jang","year":"2024","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0225","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.14218\/JCTH.2023.00272","article-title":"Antiviral therapy favors a lower risk of liver cirrhosis in HBeAg-negative chronic hepatitis B with normal alanine transaminase and HBV DNA positivity","volume":"11","author":"Zhou","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5152\/tjg.2024.23463","article-title":"Results of nucleos(t)ide analog treatment discontinuation in hepatitis B e-antigen-negative chronic hepatitis B: NUCSTOP study","volume":"35","author":"Kiremit\u00e7i","year":"2024","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0235","doi-asserted-by":"crossref","DOI":"10.1177\/13596535211067600","article-title":"Tenofovir alafenamide fumarate","volume":"27","author":"Lee","year":"2022","journal-title":"Antivir Ther"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0240","first-page":"526","article-title":"Tenofovir alafenamide (TAF) clinical pharmacology","volume":"29","author":"Di Perri","year":"2021","journal-title":"Infez Med"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0245","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1007\/s12072-021-10262-y","article-title":"Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients","volume":"15","author":"Chon","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0250","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1186\/s12879-021-06237-x","article-title":"Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B","volume":"21","author":"Li","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0255","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/liv.15208","article-title":"Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B","volume":"42","author":"Jung","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0260","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10620-022-07657-8","article-title":"Retreatment efficacy and renal safety of tenofovir alafenamide entecavir, and tenofovir disoproxil fumarate after entecavir or tenofovir cessation","volume":"68","author":"Chiu","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0265","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1185492","article-title":"Tenofovir alafenamide versus entecavir for treating hepatitis B virus-related acute-on-chronic liver failure: real-world study","volume":"14","author":"Peng","year":"2023","journal-title":"Front Microbiol"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0270","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000519440","article-title":"Real-world single-center comparison of the safety and efficacy of entecavir tenofovir disoproxil fumarate, and tenofovir alafenamide in patients with chronic hepatitis B","author":"Jeong","year":"2022","journal-title":"Intervirology"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0275","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/liv.14786","article-title":"Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia","volume":"41","author":"Li","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0280","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/hepr.13650","article-title":"Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: long-term effects from a prospective study","volume":"51","author":"Hagiwara","year":"2021","journal-title":"Hepatol Res"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0285","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/jgh3.12443","article-title":"Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B","volume":"5","author":"Itokawa","year":"2020","journal-title":"JGH Open"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0290","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/jmv.25515","article-title":"Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B","volume":"91","author":"Hagiwara","year":"2019","journal-title":"J Med Virol"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0295","first-page":"537","article-title":"Clinical ellect of tenofovir alafenamide fumarate on chronic hepatitis B patients with low viral load after entecavir treatment","volume":"38","author":"Hailin","year":"2022","journal-title":"J Clin Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0300","first-page":"89","article-title":"Analysis of the clinical antiviral efficacy of tenofovir alafenamide fuma rate in the treatment of chronic hepatitis B","volume":"8","author":"Yanxia","year":"2023","journal-title":"Syst Med"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0305","first-page":"2797","article-title":"Tenofovir alafenamide fumarate on the short-term curative effectin patients with chronic hepatitis B","volume":"30","author":"Yi","year":"2021","journal-title":"Henan Med Res"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0310","first-page":"97","article-title":"The efficacy and safety of different antiviral treatment regimens in patients with ALT elevation and low viral load in the indeterminate phase of chronic hepatitis B","volume":"44","author":"Ti","year":"2023","journal-title":"J Kunming Med Univ"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0315","first-page":"118","article-title":"Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia","volume":"31","author":"Liu","year":"2023","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0320","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.3748\/wjg.v27.i30.5088","article-title":"Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt","volume":"27","author":"Yao","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0325","article-title":"Comparison of tenofovir alafenamide and entecavir therapy in patients with chronic hepatitis B initially treated with tenofovir disoproxil: a retrospective observational survey","volume":"21","author":"Kalkan","year":"2021","journal-title":"Hepat Mon"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0330","doi-asserted-by":"crossref","first-page":"8139","DOI":"10.12998\/wjcc.v11.i34.8139","article-title":"Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir","volume":"11","author":"Yuan","year":"2023","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0335","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/jgh3.12636","article-title":"Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis","volume":"5","author":"Inada","year":"2021","journal-title":"JGH Open"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0340","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/jvh.13468","article-title":"The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: a prospective cohort study","volume":"28","author":"Zhang","year":"2021","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0345","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/liv.15086","article-title":"Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection","volume":"42","author":"Kim","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0350","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/apt.17819","article-title":"Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment","volume":"59","author":"Hong","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0355","first-page":"139","article-title":"Analysis of the clinical effect of different nucleoside (acid) analogs in the initial treatment of hepatitis B cirrhosis","volume":"8","author":"Tingqiu","year":"2022","journal-title":"World J Complex Med"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0360","first-page":"855","article-title":"Real-world study on the efficacy and safety of first-line antiviral therapy for chronic hepatitis B","volume":"31","author":"Chang","year":"2023","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0365","author":"Higgins","year":"2022","journal-title":"Cochrane handbook for systematic reviews of interventions version 6.3"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0370","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"10.1016\/j.gastrohep.2024.502276_bib0375","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jhep.2022.12.007","article-title":"Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis","volume":"78","author":"Choi","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0380","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/apt.17438","article-title":"Entecavir versus tenofovir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy","volume":"57","author":"Kao","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0385","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.40353","article-title":"Tenofovir vs entecavir among patients with HBV-related HCC after resection","volume":"6","author":"Li","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.gastrohep.2024.502276_bib0390","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s12072-021-10234-2","article-title":"Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B","volume":"15","author":"Lee","year":"2021","journal-title":"Hepatol Int"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570524002838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570524002838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T08:58:50Z","timestamp":1742633930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570524002838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0210570524002838"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2024.502276","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tenofovir alafenamide versus entecavir in treating patients with chronic hepatitis B: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2024.502276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502276"}}